Get the Stockscreener App
20.40
0.25%
0.05
After Hours:
20.30
-0.10
-0.49%
Bicycle Therapeutics Plc Adr stock is traded at $20.40, with a volume of 208.73K.
It is up +0.25% in the last 24 hours and down -16.63% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
See More
Previous Close:
$20.35
Open:
$20.36
24h Volume:
208.73K
Relative Volume:
0.67
Market Cap:
$1.41B
Revenue:
$26.98M
Net Income/Loss:
$-180.66M
P/E Ratio:
-4.359
EPS:
-4.68
Net Cash Flow:
$-63.56M
1W Performance:
-0.68%
1M Performance:
-16.63%
6M Performance:
-6.64%
1Y Performance:
+50.89%
1-Day Range:
$20.20
$20.72
1-Week Range:
$19.90
$21.45
52-Week Range:
$14.01
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
20.40 | 1.41B | 26.98M | -180.66M | -63.56M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India
Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com
Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance
Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN
A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily
BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News
Bicycle therapeutics executive sells shares worth over $21k - Investing.com India
Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India
Bicycle therapeutics COO sells shares worth over $21k - Investing.com India
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Bicycle therapeutics CTO sells shares worth over $21k - Investing.com
Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com
CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguso sale 246 shares of Bicycle Therapeutics Plc ADR [BCYC] – Knox Daily - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC)’s stock chart: A technical perspective - US Post News
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 22.56 - The Dwinnex
Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com
A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily
Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News
RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily
Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex
Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News
Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily
Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.26 % on Wednesday - Knox Daily
A stock that deserves closer examination: Bicycle Therapeutics Plc ADR (BCYC) - US Post News
Bicycle Therapeutics Plc ADR (BCYC) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone - Yahoo Finance
Aqua Metals Inc [AQMS] Shares Fall Approximately -81.89% Over the Year - Knox Daily
Taking a look at what insiders are doing to gauge the Interface Inc. [TILE] - Knox Daily
Sleep Number Corp [SNBR] Director makes an insider purchase of 43,000 shares worth 0.53 million. - Knox Daily
Top investors say Bicycle Therapeutics Plc ADR (BCYC) ticks everything they need - SETE News
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade - MSN
An Analysis of Bicycle Therapeutics Plc ADR (BCYC)’s Potential Price Growth - Knox Daily
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024 - MSN
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock - Yahoo Finance
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? - Yahoo Finance
B. Riley Securities’s latest rating for BCYC stock - Knox Daily
Bicycle Therapeutics Plc ADR (BCYC) may enjoy gains as insiders got busy in the recent days - Knox Daily
Bicycle Therapeutics Plc ADR’s latest rating changes from various analysts - Knox Daily
South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Bicycle Therapeutics Plc ADR [BCYC] Investment Appeal on the Rise – Knox Daily - Knox Daily
Is it a good time to sell Wendy's Co [WEN] shares after an insider sold 21000 shares? – Knox Daily - Knox Daily
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength? - Yahoo Movies UK
Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up - Yahoo News Malaysia
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Soars 19.3%: Is Further Upside Left in the Stock? - Yahoo Sport Australia
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):